Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-world data of first-line treatment with pembrolizumab for NSCLC with high PD-L1 expression in elderly patients: a subgroup analysis of HOT/NJLCG2001.
Tateishi K, Mizugaki H, Ikezawa Y, Morita R, Yokoo K, Sumi T, Aso M, Kikuchi H, Nakamura A, Sekikawa M, Yoshiike F, Kitamura Y, Kimura N, Hachiya T, Tsurumi K, Agatsuma T, Megumi F, Nakamura K, Jingu D, Yamamoto H, Kosaka M, Yokouchi H. Tateishi K, et al. Among authors: mizugaki h. Jpn J Clin Oncol. 2024 Dec 4:hyae168. doi: 10.1093/jjco/hyae168. Online ahead of print. Jpn J Clin Oncol. 2024. PMID: 39656678
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with oncogene-addicted metastatic non-small-cell lung cancer.
Lee SH, Menis J, Kim TM, Kim HR, Zhou C, Kurniawati SA, Prabhash K, Hayashi H, Lee DD, Imasa MS, Teh YL, Yang JC, Reungwetwattana T, Sriuranpong V, Wu CE, Ang Y, Sabando M, Thiagarajan M, Mizugaki H, Noronha V, Yulianti M, Zhang L, Smyth E, Yoshino T, Park JO, Pentheroudakis G, Park S, Peters S, Ahn JB, Popat S. Lee SH, et al. Among authors: mizugaki h. ESMO Open. 2024 Dec;9(12):103996. doi: 10.1016/j.esmoop.2024.103996. Epub 2024 Nov 29. ESMO Open. 2024. PMID: 39615406 Free PMC article.
Phase I study of the safety and clinical activity of the interleukin-8 inhibitor AMY109 combined with atezolizumab in patients with advanced solid cancers.
Yamamoto N, Kitano S, Koyama T, Ikeda M, Mizugaki H, Narikiyo T, Yamaguchi Y, Ishida T, Takubo R, Ogami C, Sekiya M, Nakagawa Y, Kuboki Y. Yamamoto N, et al. Among authors: mizugaki h. J Immunother Cancer. 2024 Jul 24;12(7):e009262. doi: 10.1136/jitc-2024-009262. J Immunother Cancer. 2024. PMID: 39053945 Free PMC article. Clinical Trial.
Real-world first-line treatment with pembrolizumab for non-small cell lung carcinoma with high PD-L1 expression: Updated analysis.
Ikezawa Y, Morita R, Mizugaki H, Tateishi K, Yokoo K, Sumi T, Kikuchi H, Kitamura Y, Nakamura A, Kobayashi M, Aso M, Kimura N, Yoshiike F, Megumi F, Tanaka H, Sekikawa M, Hachiya T, Nakamura K, Hommura F, Sukoh N, Ito K, Kikuchi T, Agatsuma T, Yokouchi H. Ikezawa Y, et al. Among authors: mizugaki h. Cancer Med. 2024 Jul;13(14):e70036. doi: 10.1002/cam4.70036. Cancer Med. 2024. PMID: 39030894 Free PMC article.
Multicenter Pharmacokinetic and Pharmacodynamic Study of Pembrolizumab for Non-small-Cell Lung Cancer in Patients Aged 75 Years and Older.
Yagishita S, Yamanaka Y, Kurata T, Watanabe K, Hosomi Y, Horinouchi H, Ohe Y, Nakahara Y, Naoki K, Asao T, Takahashi K, Saeki S, Sakagami T, Nakashima K, Tsubata Y, Fujita Y, Wakui H, Furuta M, Konishi JS, Ohuchi M, Ando Y, Mizugaki H, Hamada A. Yagishita S, et al. Among authors: mizugaki h. Clin Pharmacol Ther. 2024 Oct;116(4):1042-1051. doi: 10.1002/cpt.3339. Epub 2024 Jun 17. Clin Pharmacol Ther. 2024. PMID: 38887810
Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: Results from the multicenter, phase 2 REMORA trial.
Niho S, Sato J, Satouchi M, Itoh S, Okuma Y, Mizugaki H, Murakami H, Fujisaka Y, Kozuki T, Nakamura K, Machida R, Ohe Y, Tamai T, Ikezawa H, Yamamoto N. Niho S, et al. Among authors: mizugaki h. Lung Cancer. 2024 May;191:107557. doi: 10.1016/j.lungcan.2024.107557. Epub 2024 Mar 30. Lung Cancer. 2024. PMID: 38626709 Free article. Clinical Trial.
Durvalumab after chemoradiotherapy in non-small cell lung cancer with EGFR mutation: A real-world study (HOT2101).
Tsuji K, Mizugaki H, Yokoo K, Kobayashi M, Kawashima Y, Kimura N, Yokouchi H, Kikuchi H, Sumi T, Kawai Y, Kobashi K, Morita R, Ito K, Kitamura Y, Minemura H, Nakamura K, Aso M, Honjo O, Tanaka H, Takashina T, Tsurumi K, Sugisaka J, Tsukita Y, Konno S, Oizumi S. Tsuji K, et al. Among authors: mizugaki h. Cancer Sci. 2024 Apr;115(4):1273-1282. doi: 10.1111/cas.16094. Epub 2024 Jan 29. Cancer Sci. 2024. PMID: 38287788 Free PMC article.
Ganglioside GM3 deficiency enhances mast cell sensitivity.
Komuro M, Mizugaki H, Nagane M, Morimoto M, Fukuyama T, Ogihara K, Naya Y, Yokomori E, Kaneshima K, Kawakami Y, Kamiie J, Shibata Y, Suzuki M, Shimizu T, Kawashima N, Okamoto M, Ikeda T, Yamashita T. Komuro M, et al. Among authors: mizugaki h. FEBS J. 2023 Sep;290(17):4268-4280. doi: 10.1111/febs.16806. Epub 2023 May 5. FEBS J. 2023. PMID: 37098812 Free article.
46 results